296 related articles for article (PubMed ID: 36995386)
1. [Myasthenia in adults, children, and adolescents: what's new?].
Stascheit F; Della Marina A; Meisel A
Nervenarzt; 2023 Jun; 94(6):501-509. PubMed ID: 36995386
[TBL] [Abstract][Full Text] [Related]
2. Guideline for the management of myasthenic syndromes.
Wiendl H; Abicht A; Chan A; Della Marina A; Hagenacker T; Hekmat K; Hoffmann S; Hoffmann HS; Jander S; Keller C; Marx A; Melms A; Melzer N; Müller-Felber W; Pawlitzki M; Rückert JC; Schneider-Gold C; Schoser B; Schreiner B; Schroeter M; Schubert B; Sieb JP; Zimprich F; Meisel A
Ther Adv Neurol Disord; 2023; 16():17562864231213240. PubMed ID: 38152089
[TBL] [Abstract][Full Text] [Related]
3. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
4. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
7. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
8. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
Heo YA
CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
Menon D; Bril V
Drugs; 2022 Jun; 82(8):865-887. PubMed ID: 35639288
[TBL] [Abstract][Full Text] [Related]
10. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
Vu T; Ortiz S; Katsuno M; Annane D; Mantegazza R; Beasley KN; Aguzzi R; Howard JF
J Neurol; 2023 Jun; 270(6):3129-3137. PubMed ID: 36890354
[TBL] [Abstract][Full Text] [Related]
11. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
12. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
Dalakas MC
Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
[TBL] [Abstract][Full Text] [Related]
13. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Curr Opin Rheumatol; 2019 Nov; 31(6):623-633. PubMed ID: 31385879
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab: A Review in Generalized Myasthenia Gravis.
Dhillon S
Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
[TBL] [Abstract][Full Text] [Related]
18. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G; Putko BN; Wagner AN; Siddiqi ZA
Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Lien PW; Joshi M; Tice JA; Agboola F; Nikitin D; Withanawasam V; Jatoi S; Touchette DR
J Manag Care Spec Pharm; 2024 Jun; 30(6):517-527. PubMed ID: 38824625
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
